Items where authors include "Chiu, C"

Article

Zhou, J, Singanayagam, A, Goonawardane, N et al. (11 more authors) (2023) Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study. The Lancet Microbe, 4 (8). E579-E590. ISSN 2666-5247

Bahlis, NJ, Dimopoulos, MA, White, DJ et al. (16 more authors) (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia, 34. pp. 1875-1884. ISSN 0887-6924

Mateos, M-V, Spencer, A, Nooka, AK et al. (16 more authors) (2019) Daratumumab-Based Regimens Are Highly Effective And Well Tolerated In Relapsed Or Refractory Multiple Myeloma Regardless Of Patient Age: Subgroup Analysis Of The Phase 3 CASTOR And POLLUX Studies. Haematologica. ISSN 0390-6078

Dimopoulos, MA, San-Miguel, J, Belch, A et al. (30 more authors) (2018) Daratumumab Plus Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of POLLUX. Haematologica, 103 (12). pp. 2088-2096. ISSN 0390-6078

Proceedings Paper

Bahlis, N, Dimopoulos, MA, White, DJ et al. (14 more authors) (2018) Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Moreau, P, White, D, Benboubker, L et al. (12 more authors) (2018) Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux). In: Haematologica: the hematology journal. 1st European Myeloma Network Meeting, 19-21 Apr 2018, Turin, Italy. Ferrata Storti Foundation , p. 31.